Overactive Bladder (OAB) is a common, disabling condition associated with considerable negative impact on quality of life, quality of sleep, and mental health. The age-specific prevalence of OAB is similar among males and females. Urge incontinence affects only a portion of the OAB population: 33% of patients have OAB with urge incontinence ("OAB wet"), while 66% have OAB without urge incontinence ("OAB dry"). The symptoms of OAB can affect social, psychological, occupational, domestic, physical, and sexual aspects of life.

The International Continence Society (ICS) defines OAB as a complex of symptoms that include urinary urgency, with or without UI, and additional features that include frequency and nocturia. The symptoms of OAB are often unreported by patients and are thus undertreated by clinicians. The NOBLE survey reported that OAB affects more than 30 million Americans, with a prevalence of 17% in women and 16% in men.

Global sales of OAB drugs exceed 2 Billion dollars per year and yet over 80% of patients taking OAB medications will stop for either lack of efficacy, side effects or both. Refractory OAB represent an unmet medical need and the market represents a significant opportunity estimated at 400 to 800 million dollars per year.